This result clearly suggests that in combination with Nrf2 inhibitors the anti-cancer properties of RRx-001 will be enhanced, while RRx-001-induced activation of Nrf2 may have beneficial effects on ROS-mediated diseases like diabetes, rheumatoid arthritis and atherosclerosis. Here, NFE2L2 is linked to atherosclerosis.